Navigation Links
Agendia Wins 2011 Scrip Award for "Best Partnership Alliance"
Date:2/29/2012

IRVINE, Calif. and AMSTERDAM, Feb. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that the company is a recipient of the 2011 Scrip Award for "Best Partnership" for its cooperative alliance between Agendia, AstraZeneca and the Netherlands Cancer Institute (NKI). This is the seventh annual competition to recognize and honor achievements throughout the pharmaceutical industry.

The collaboration between Agendia, AstraZeneca and NKI represents a new approach to personalized diagnostics with the goal of accelerating the delivery of promising personalized therapies to patients by segmenting colorectal cancer at the molecular level.

"This is a model of how bio/pharma and academia can work in new paradigms involving a biotech, a pharma and a major academic research center," panel judges on behalf of Scrip said of the partnership. "This has the potential to pioneer new understanding of colorectal cancer and result in new diagnostics to understand a personalized approach to the treatment of this disease that does not now exist."

Scrip, the leading source for global pharmaceutical industry news, gathers highly respected and independent experts from throughout the pharmaceutical industry to recognize innovations across the field including research, clinical trials and breakthrough drugs. The Best Partnership Alliance award acknowledges the importance of partnerships involving pharmaceutical and biotech companies in developing novel therapeutics.

"This award recognizes the unique alliance that brings together high-level academic research as well as companies known for the successful development of molecular diagnostics and targeted therapies," said David Macdonald, Agendia's CEO. "A key feature of this collaboration is that personalized medicine can be developed much more quickly by combining the different expertise of each of the three individual partners from the beginning. The collaboration began in 2011 and is already producing interesting leads."

About Agendia:
Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.

For further information, please contact:

Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300
E-mail: todd@ricochetpr.com


'/>"/>
SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue
2. Agendia Appoints New CEO and Supervisory Board Member
3. Agendia Receives €1.27 Million in Funding from the EUs Seventh Framework Programme
4. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
5. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
6. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
7. FDA Broadens Clearance for Agendias MammaPrint(R)
8. /C O R R E C T I O N -- Agendia B.V./
9. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
10. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
11. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016 Sanovas, Inc., ... accelerator, announced today the launch of its wholly owned subsidiary, ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... ... There are ...
(Date:12/5/2016)... -- Wellbridge Health and Gateway Health proudly announce a dynamic collaboration ... Medicaid plan members with specific high risk needs. ... this group of consumers, Wellbridge combines technology and population expertise ... into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating ... Scooters give freedom to people who need help getting around. For some, advancing age ... long period of rehabilitation after an illness or accident. There is a wide variety ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... magazine’s 2017 Training Top 125 for their industry leading training methods that engage ... recognizes USA as among the global elite in employer-sponsored training and development programs. ...
(Date:12/5/2016)... ... 2016 , ... Edward Buckingham MD , and the ... the newest Sciton laser in January 2017. The Halo is the first and ... wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically customizes ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... Novato, CA (PRWEB) , ... December 05, 2016 ... ... company, has extended its partnership with leading global lifestyle design firm kathy ireland® ... , Worldwise® and kathy ireland® Worldwide entered into an exclusive licensing agreement three ...
Breaking Medicine News(10 mins):